König E, Bartels H, Bremer K, Burger-Schüler A, Common H, Dühmke E, Engelhard M, Fülle H H, Gunzer U, Koeppen K M, Leopold H, Nowicki L, Oertel J, Paetzmann S, Rühl U, Schmidt M, Schoengen A, Scholle H, Stacher A, Wolf-Hornung B, Schwarze E W, Brittinger G
Blut. 1981 Sep;43(3):193-200. doi: 10.1007/BF00363889.
Clinical data of 48 patients with centrocytic, 83 patients with centroblastic/centrocytic and 64 patients with centroblastic lymphoma who had entered a prospective multicenter study of the Kiel Lymphoma Study Group since October 1975 were compared. Advanced (stage IV) disease at time of diagnosis, predominantly due to bone marrow infiltration, was most frequent in centrocytic (69% of patients) and in centroblastic/centrocytic (51% of patients) lymphomas as compared to only 28% of patients with centroblastic lymphoma. High survival probability of patients with localized centrocytic and centroblastic/centrocytic lymphomas after radiotherapy, contrasting with a worse prognosis of corresponding patients with centroblastic lymphoma, is compatible with the classification of these lymphoma entities as neoplasias of low-grade malignancy. However, as shown by this prospective and previous retrospective trials overall survival probability of patients with advanced centrocytic lymphoma was inferior to that observed in corresponding patients with centroblastic/centrocytic lymphoma. These findings suggest the possibility that patients with advanced centrocytic lymphoma occupy an intermediate position between typical low-grade and typical high-grade malignant non-Hodgkin lymphomas.
对自1975年10月起参加基尔淋巴瘤研究组前瞻性多中心研究的48例中心细胞性淋巴瘤患者、83例中心母细胞性/中心细胞性淋巴瘤患者和64例中心母细胞性淋巴瘤患者的临床数据进行了比较。诊断时的晚期（IV期）疾病主要由于骨髓浸润，在中心细胞性淋巴瘤（69%的患者）和中心母细胞性/中心细胞性淋巴瘤（51%的患者）中最为常见，而中心母细胞性淋巴瘤患者中仅占28%。局限性中心细胞性和中心母细胞性/中心细胞性淋巴瘤患者放疗后的高生存概率，与相应的中心母细胞性淋巴瘤患者较差的预后形成对比，这与将这些淋巴瘤实体归类为低级别恶性肿瘤相一致。然而，正如本次前瞻性试验和以往回顾性试验所示，晚期中心细胞性淋巴瘤患者的总生存概率低于相应的中心母细胞性/中心细胞性淋巴瘤患者。这些发现提示晚期中心细胞性淋巴瘤患者可能处于典型的低级别和典型的高级别恶性非霍奇金淋巴瘤之间的中间位置。
